exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087729 RNA Name: hsa-miR-1297 RNA Type: miRNA Chromosome: chr13 Starnd: - Coordinate: Start Site(bp): 54311981 End Site(bp): 54311997 External Links: hsa-miR-1297

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand NID1 chr1 235975830 236065109 - SLC26A2 chr5 149960758 149993455 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000120 chr1 117944807 118009049 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005082.1 chr7 23205787 23208045 + AC016026.1 chr22 17787652 17811497 - AC068768.1 chr12 123262060 123262402 + AC144548.1 chr12 110387463 110445548 - AL122035.1 chr14 64422935 64448557 - AL137127.1 chr1 19072110 19075511 - AL358472.3 chr1 153966516 153966930 + ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - GAS5 chr1 173858559 173868882 - HCG11 chr6 26521709 26527404 + LINC00205 chr21 45288050 45297806 + LINC00240 chr6 26956932 27059749 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - RRN3P2 chr16 29074976 29116718 + SNHG5 chr6 85650491 85678932 - SNHG6 chr8 66921684 66926398 - TUG1 chr22 30969245 30979395 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.